Combination of Imatinib Mesylate and AKT Inhibitor Provides Synergistic Effects in Preclinical Study of Gastrointestinal Stromal Tumor

PURPOSE: Gastrointestinal stromal tumors (GIST) generally harbor activating mutations in the receptor tyrosine kinase KIT or in the related platelet derived growth factor receptor alpha (PDGFRA). GIST treated with imatinib mesylate (IM) or second-line therapies that target mutant forms of these rece...

Full description

Saved in:
Bibliographic Details
Published in:Clin Cancer Res
Main Authors: Zook, Phillip, Pathak, Harsh B., Belinsky, Martin G., Gersz, Lawrence, Devarajan, Karthik, Zhou, Yan, Godwin, Andrew K., von Mehren, Margaret, Rink, Lori
Format: Artigo
Language:Inglês
Published: 2016
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5203981/
https://ncbi.nlm.nih.gov/pubmed/27370604
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-16-0529
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items